Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.33 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.33 |
| ▸ | PTPRC | P08575 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.32 |
| ▸ | RELA | Q04206 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5369960 | 1.00 | CYSLTR2 (0.33) | CYSLTR2CYSLTR1PTPN1PTPRCKDM4E | |
| SCHEMBL5335091 | 0.91 | CYSLTR2 (0.36) | CYSLTR2CYSLTR1PTPN1PTPRCKDM4E | |
| SCHEMBL5335095 | 0.91 | CYSLTR2 (0.36) | CYSLTR2CYSLTR1PTPN1PTPRCKDM4E | |
| SCHEMBL5337057 | 0.86 | CYSLTR2 (0.36) | CYSLTR2CYSLTR1PTPN1PTPRCKDM4E | |
| SCHEMBL5337055 | 0.86 | CYSLTR2 (0.36) | CYSLTR2CYSLTR1PTPN1PTPRCKDM4E | |
| SCHEMBL5338648 | 0.83 | CYSLTR1 (0.40) | CYSLTR2CYSLTR1PTPN1PTPRC | |
| SCHEMBL5338653 | 0.83 | CYSLTR1 (0.40) | CYSLTR2CYSLTR1PTPN1PTPRC | |
| SCHEMBL5338662 | 0.83 | KDM4E (0.36) | CYSLTR2CYSLTR1KDM4ENPC1ALDH1A1 | |
| SCHEMBL5338657 | 0.83 | KDM4E (0.36) | CYSLTR2CYSLTR1KDM4ENPC1ALDH1A1 | |
| SCHEMBL5339229 | 0.82 | CYSLTR1 (0.42) | CYSLTR2CYSLTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7309718-B2 | Dibenzocycloheptene compound | UBE INDUSTRIES, LTD. (JP) | 2007-12-18 | — | — | US | disclosed |
| US-20040180884-A1 | Dibenzocycloheptene compound | UBE INDUSTRIES, LTD. (JP) | 2004-09-16 | — | — | US | disclosed |
| EP-1408033-A1 | DIBENZOCYCLOHEPTENE COMPOUND | Ube Industries, Ltd. (JP) | 2004-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180884-A1 | Dibenzocycloheptene compound | LTB4R2, LTA4H, LTC4S | CYSLTR2 5/4885CYSLTR1 6/4885PTPN1 2636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.